Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $7.88
Previous CloseN/A
Volume228.85K
Average Volume (3M)156.06K
Market Cap
$65.02M
Enterprise Value$47.82M
Total Cash (Recent Filing)$3.76M
Total Debt (Recent Filing)$29.71M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
May 07, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding33,570,250
10 Day Avg. Volume125,317
30 Day Avg. Volume156,056
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.51
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$10.00Price Target Upside792.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Earnings Call: Tech Gains Amid Financial Strains
PremiumCompany Announcements
Rani Therapeutics Reports 2024 Financial Results and Updates---
Bulls Say, Bears Say
Bulls Say
Financial StabilityRani expects its cash runway to last into 3Q25 without additional funding, which suggests financial stability.
Market OpportunityThe obesity market opportunity is large (projected to eclipse $100B by 2030), so there is a sizeable opportunity for RT-114 as a more tolerable, orally administered Tx option with a biologic payload.
Strategic DevelopmentThe initiation of a Phase 1 trial for RT-114 in obesity, utilizing innovative RaniPill capsule technology, represents a significant development step.
Bears Say
Partnership And Market RisksRisks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.
Regulatory And Clinical RisksRisks include potential negative Phase 2 data and failure to achieve approvals for key pipeline projects.
---
Options Prices
Currently, No data available
---
Ownership Overview
27.49% Insiders
2.73% Mutual Funds
5.78% Other Institutional Investors
61.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.03 and its highest was $7.88 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $65.02M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Mar 31, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.01.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -0.27.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 33,570,250 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -2.381%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (792.86% Upside)
$10.00 (792.86% Upside)
Insider Transactions
Bought Shares
Worth $30.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.97%
12-Months-Change
Fundamentals
Return on Equity
-404.07%
Trailing 12-Months
Asset Growth
-36.75%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
---
RANI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Read More>---
RANI Stock 12 Month Forecast
Average Price Target
$10.00
▲(792.86% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Adverum Biotechnologies
―
IGM Biosciences
―
Adagene
―
TScan Therapeutics
―
Best Analysts Covering RANI
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-31.38%
reiterated a buy rating 27 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -31.38% per trade.
---